Lehman Bros. Downgrades Gilead Sciences (GILD) to Equalweight
More News related to GILD
- Gilead Sciences to Present at Two Upcoming Investor Conferences
- Gilead Sciences Announces Notification of ANDA Filing for Truvada
- David Moenning's Daily State of the Markets: 11/12
- Notable Analyst Rating Changes 11/12: BBBY, PAG, ROK Upgraded; EGLE, FMCN, BRCM Downgraded
- Needham & Co Initiates Coverage on Gilead Sciences (GILD), Represents Core Holding
More News related to Downgrades
- ION Geophysical (IO) Director Buys 50K Shares
- Sunstone Hotel Investors (SHO) CFO Buys 20K Shares
- Dillard's (DDS) Director White Buys 27K Shares
- Strategic Hotels & Resorts (BEE) CEO Buys 39.5K Shares
- Caribou Coffee (CBOU) CEO Buys 11.9K Shares
Lehman Bros. downgrades Gilead Sciences (Nasdaq: GILD) from Overweight to Equalweight.
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need.
Related Categories
DowngradesStocks Mentioned
-2.33Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
